Jerald Radich

Jerald Radich

UNVERIFIED PROFILE

Are you Jerald Radich?   Register this Author

Register author
Jerald Radich

Jerald Radich

Publications by authors named "Jerald Radich"

Are you Jerald Radich?   Register this Author

100Publications

3202Reads

37Profile Views

New approaches of molecular monitoring in CML (and other diseases).

Blood 2019 Sep 18. Epub 2019 Sep 18.

Laboratory Medicine, University of Washington, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019000838DOI Listing
September 2019

Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.

Clin Lymphoma Myeloma Leuk 2019 Jun 14;19(6):e281-e290. Epub 2019 Feb 14.

Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.02.001DOI Listing
June 2019

A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.

Leuk Lymphoma 2019 Apr 24:1-8. Epub 2019 Apr 24.

a Department of Medicine Division of Oncology , University of Washington , Seattle , WA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1605508DOI Listing
April 2019

Is DNA a better assay for residual disease in chronic myeloid leukemia?

Authors:
Jerald Radich

Haematologica 2018 12 30;103(12):1942-1944. Epub 2018 Nov 30.

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269307PMC
December 2018

Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.

Am J Hematol 2018 08 27;93(4):546-552. Epub 2018 Jan 27.

Department of Medicine, University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25030DOI Listing
August 2018

Self-digitization chip for single-cell genotyping of cancer-related mutations.

PLoS One 2018 2;13(5):e0196801. Epub 2018 May 2.

Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196801PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931502PMC
July 2018

There is nothing minimal about residual disease.

Authors:
Jerald P Radich

Blood 2018 03;131(12):1269-1270

Fred Hutchinson Cancer Research Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-01-824870DOI Listing
March 2018

Predicting Chemotherapy Resistance in AML.

Curr Hematol Malig Rep 2017 12;12(6):530-536

Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, G7-910, Seattle, WA, 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0378-xDOI Listing
December 2017

Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.

Hematol Oncol Clin North Am 2017 08;31(4):577-587

Myeloproliferative Neoplasms Program, Leukemia Section, Memorial Sloan Kettering Cancer Center, 1275 York Avenue (Between 67th and 68th street), New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2017.04.006DOI Listing
August 2017

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.

Blood 2017 08 11;130(9):1170-1172. Epub 2017 Jul 11.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-03-771121DOI Listing
August 2017

Chronic myeloid leukemia: Global impact from a local laboratory.

Authors:
Jerald P Radich

Cancer 2017 07 6;123(14):2594-2596. Epub 2017 Jun 6.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.30776
Publisher Site
http://dx.doi.org/10.1002/cncr.30776DOI Listing
July 2017

CHIPs and engraftment dips.

Blood 2017 07;130(1):7-9

FRED HUTCHINSON CANCER RESEARCH CENTER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-05-782664DOI Listing
July 2017

Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.

Biol Blood Marrow Transplant 2017 Apr 3;23(4):691-696. Epub 2017 Jan 3.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.12.639DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465962PMC
April 2017

Understanding CML, 1 cell at a time.

Authors:
Jerald Radich

Blood 2017 04;129(17):2339-2340

FRED HUTCHINSON CANCER RESEARCH CENTER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-02-765578DOI Listing
April 2017

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

N Engl J Med 2017 03;376(10):917-927

From Abteilung Hämatologie-Onkologie, Universitätsklinikum Jena, Jena, Germany (A.H.); the Department of Medicine, University of Chicago, Chicago (R.A.L.); INSERM Centre d'Investigation Clinique 1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (F.G.); Fred Hutchinson Cancer Research Center, Seattle (J.P.R.); Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide (S.B.), and the South Australian Health and Medical Research Institute and University of Adelaide (T.P.H.), Adelaide, SA, Australia; University of Bologna, Bologna, Italy (M.B.); the University of Utah Huntsman Cancer Institute, Salt Lake City (M.W.D.); the Hematology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (F.C.); Novartis, Basel, Switzerland (S.F., C.-E.O., H.D.M.); M.D. Anderson Cancer Center, Houston (H.K.); the University of Newcastle, Newcastle, United Kingdom (S.G.O.); and Knight Cancer Institute, Oregon Health and Science University and Howard Hughes Medical Institute, Portland (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965PMC
March 2017

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

J Clin Oncol 2017 Feb 21;35(4):394-401. Epub 2016 Nov 21.

Kathryn G. Roberts, Zhaohui Gu, Debbie Payne-Turner, Kelly McCastlain, Deqing Pei, Ilaria Iacobucci, Marcus Valentine, Stanley B. Pounds, Lei Shi, Yongjin Li, Jinghui Zhang, Cheng Cheng, and Charles G. Mullighan, St Jude Children's Research Hospital, Memphis, TN; Richard C. Harvey, I-Ming Chen, and Cheryl L. Willman, University of New Mexico Cancer Center, Albuquerque, NM; Alessandro Rambaldi, Manuela Tosi, and Orietta Spinelli, Ospedale Papa Giovanni XXIII, Bergamo, Italy; Jerald P. Radich, Fred Hutchinson Cancer Research Center, Seattle, WA; Mark D. Minden, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Jacob M. Rowe, Shaare Zedek Medical Center, Jerusalem, Israel; Selina Luger, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Mark R. Litzow, Mayo Clinic, Rochester, MN; Martin S. Tallman, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York; Peter H. Wiernik, Cancer Research Foundation of New York; Elisabeth Paietta, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Ravi Bhatia, The University of Alabama at Birmingham, Birmingham, AL; Ibrahim Aldoss and Guido Marcucci, City of Hope, Duarte, CA; Jessica Kohlschmidt, Krzysztof Mrózek, and Clara D. Bloomfield, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; Wendy Stock, University of Chicago Medical Center, Chicago, IL; and Stephen Kornblau, Hagop M. Kantarjian, and Marina Konopleva, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.0073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455698PMC
February 2017

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

J Natl Compr Canc Netw 2016 12;14(12):1505-1512

From St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Memorial Sloan Kettering Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Stanford Cancer Institute; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; Fox Chase Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Roswell Park Cancer Institute; University of Colorado Cancer Center; University of Michigan Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; UCSF Helen Diller Family Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; Mayo Clinic Cancer Center; University of Wisconsin Carbone Cancer Center; National Comprehensive Cancer Network; Huntsman Cancer Institute at the University of Utah; and Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0162DOI Listing
December 2016

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2016 11 17;22(11):1974-1982. Epub 2016 Aug 17.

Myeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072749PMC
http://dx.doi.org/10.1016/j.bbmt.2016.08.014DOI Listing
November 2016

Molecular monitoring of chronic myeloid leukemia: present and future.

Expert Rev Mol Diagn 2016 10 6;16(10):1083-1091. Epub 2016 Sep 6.

c Fred Hutchinson Cancer Research Center , Seattle , WA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2016.1227243DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161535PMC
October 2016

Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL.

Best Pract Res Clin Haematol 2016 09 20;29(3):252-263. Epub 2016 Oct 20.

Clinical Research Division, Fred Hutchinson Cancer Research Center, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.10.015DOI Listing
September 2016

When to Consider Allogeneic Transplantation in CML.

Authors:
Jerald Radich

Clin Lymphoma Myeloma Leuk 2016 08;16 Suppl:S93-5

Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650160006
Publisher Site
http://dx.doi.org/10.1016/j.clml.2016.02.008DOI Listing
August 2016

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

Am J Hematol 2016 07 24;91(7):742-6. Epub 2016 May 24.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24381
Publisher Site
http://dx.doi.org/10.1002/ajh.24381DOI Listing
July 2016

Management of Advanced-Phase Chronic Myelogenous Leukemia.

Authors:
Jerald P Radich

J Natl Compr Canc Netw 2016 05;14(5 Suppl):669-71

Presented by Jerald P. Radich, MD, Fred Hutchinson Cancer Research Center/University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0188DOI Listing
May 2016

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Leuk Lymphoma 2015 14;56(8):2315-25. Epub 2015 Jan 14.

a Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment , UMIT - University for Health Sciences, Medical Informatics and Technology , Hall in Tirol , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.982635DOI Listing
April 2016

New Methodologies in the Molecular Monitoring of CML.

Curr Hematol Malig Rep 2016 Apr;11(2):94-101

Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, G7-910, Seattle, WA, 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-016-0303-8DOI Listing
April 2016

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia.

Sci Rep 2016 Apr 6;6:24057. Epub 2016 Apr 6.

Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52062 Aachen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep24057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822142PMC
April 2016

From molecular interaction to acute promyelocytic leukemia: Calculating leukemogenesis and remission from endogenous molecular-cellular network.

Sci Rep 2016 Apr 21;6:24307. Epub 2016 Apr 21.

Key Laboratory of Systems Biomedicine, Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep24307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838884PMC
April 2016

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.

Leuk Res 2016 Mar 15;42:68-74. Epub 2016 Jan 15.

Oncology Research Institute, Loyola University Health Sciences Division, Maywood, IL 60153, United States; Division of Hematology & Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779662PMC
March 2016

Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?

Curr Opin Hematol 2016 Mar;23(2):115-20

aPharmaceutical Outcomes Research and Policy Program, University of Washington bPublic Health Sciences Division, Fred Hutchinson Cancer Research Center cClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-hematology/2016/03000/Is_cur
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/MOH.0000000000000224DOI Listing
March 2016

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

J Clin Oncol 2016 Feb 14;34(4):329-36. Epub 2015 Dec 14.

Daisuke Araki, Brent L. Wood, Jerald P. Radich, Anna B. Halpern, Yi Zhou, Marco Mielcarek, Elihu H. Estey, Frederick R. Appelbaum, and Roland B. Walter, University of Washington; and Megan Othus, Jerald P. Radich, Marco Mielcarek, Elihu H. Estey, Frederick R. Appelbaum, and Roland B. Walter, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.3826DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872033PMC
February 2016

What Happens When Imatinib Goes Generic?

J Natl Compr Canc Netw 2016 Feb;14(2):128-31

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0016DOI Listing
February 2016

Optimizing Patient Care in Chronic Phase Chronic Myelogenous Leukemia: A Multidisciplinary Approach

J Natl Compr Canc Netw 2016 Jan;14(14 Suppl 1):S1-S6

Molecular Oncology Laboratory at Fred Hutchinson Cancer Research Center, and University of Washington School of Medicine, Seattle, Washington

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0197DOI Listing
January 2016

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.

Leuk Res Treatment 2015 10;2015:982395. Epub 2015 Dec 10.

Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall in Tirol, Austria; Area Health Technology Assessment, ONCOTYROL-Center for Personalized Cancer Medicine, Karl-Kapferer-Straße 5, 6020 Innsbruck, Austria; Center for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, 718 Huntington Avenue, Boston, MA 02215, USA; Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 101 Merrimac Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/982395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689963PMC
January 2016

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Splicing up the classification of myelodysplasia.

Authors:
Jerald Radich

Blood 2015 Jul;126(2):128-9

FRED HUTCHINSON CANCER RESEARCH CENTER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-05-645713DOI Listing
July 2015

Prognosis and Molecular Monitoring in Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2015 Jun;15 Suppl:S109-13

Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650150012
Publisher Site
http://dx.doi.org/10.1016/j.clml.2015.03.015DOI Listing
June 2015

Sequencing small genomic targets with high efficiency and extreme accuracy.

Nat Methods 2015 May 6;12(5):423-5. Epub 2015 Apr 6.

Department of Pathology, University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nmeth.3351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414912PMC
May 2015

Treatment milestones in chronic myelogenous leukemia: stay the course or change therapy?

Authors:
Jerald P Radich

J Natl Compr Canc Netw 2015 May;13(5 Suppl):697-9

Presented by Jerald P. Radich, MD, Director of the Molecular Oncology Laboratory at Fred Hutchinson Cancer Research Center, and Professor of Medicine at University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0207DOI Listing
May 2015

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

J Clin Oncol 2015 Apr 23;33(10):1157-64. Epub 2015 Feb 23.

Fabiana Ostronoff, Megan Othus, Elihu Estey, Frederick R. Appelbaum, Kenneth J. Kopecky, Min Fang, Vivian G. Oehler, Era L. Pogosova-Agadjanyan, Jerald P. Radich, Soheil Meshinchi, and Derek L. Stirewalt, Fred Hutchinson Cancer Research Center; Fabiana Ostronoff, Elihu Estey, Frederick R. Appelbaum, Min Fang, Vivian G. Oehler, Jerald P. Radich, and Derek L. Stirewalt, University of Washington; Stephen H. Petersdorf, Seattle Genetics, Seattle, WA; Michelle Lazenby, Anna Evans, Amanda Gilkes, and Alan Burnett, Cardiff University School of Medicine, Cardiff, United Kingdom; John Godwin, Providence Cancer Center Group and Earle A. Chiles Research Institute, Portland, OR; Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; and Cheryl L. Willman, University of New Mexico, Albuquerque, NM.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/10/1157.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.0571
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.0571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372852PMC
April 2015

Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.

Biol Blood Marrow Transplant 2015 Jan 6;21(1):184-9. Epub 2014 Oct 6.

Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.09.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464836PMC
January 2015

Self-digitization microfluidic chip for absolute quantification of mRNA in single cells.

Anal Chem 2014 Dec 25;86(24):12308-14. Epub 2014 Nov 25.

Department of Chemistry, University of Washington , Seattle, Washington 98195, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ac5035924DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270397PMC
December 2014

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.

Arch Pathol Lab Med 2014 Sep 5;138(9):1186-92. Epub 2013 Dec 5.

From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey (Dr Goldberg); Biostatistics (Dr Warsi) and Oncology Clinical Development (Dr Ericson), Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; the Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York (Dr Wetzler); and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (Dr Radich).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2013-0584-OADOI Listing
September 2014

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.

Biol Blood Marrow Transplant 2014 Sep 27;20(9):1274-81. Epub 2014 Mar 27.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.03.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465357PMC
September 2014

Structure, function, and resistance in chronic myeloid leukemia.

Authors:
Jerald Radich

Cancer Cell 2014 Sep;26(3):305-306

Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108140033
Publisher Site
http://dx.doi.org/10.1016/j.ccr.2014.08.010DOI Listing
September 2014

Medical decision analysis for first-line therapy of chronic myeloid leukemia.

Leuk Lymphoma 2014 Aug 6;55(8):1758-67. Epub 2014 Feb 6.

Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology , Hall i.T. , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.858149DOI Listing
August 2014

Integrating current treatment options for TKI-resistant chronic myeloid leukemia.

Clin Adv Hematol Oncol 2014 Jul;12(7 Suppl 13):3-17, 1

Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
July 2014

Monitoring molecular response to tyrosine kinase therapy in chronic myelogenous leukemia.

Authors:
Jerald P Radich

J Natl Compr Canc Netw 2014 May;12(5 Suppl):817-20

Presented by Jerald P. Radich, MD, Director, Molecular Oncology Lab, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0197DOI Listing
May 2014

Systematic assessment of decision-analytic models for chronic myeloid leukemia.

Appl Health Econ Health Policy 2014 Apr;12(2):103-15

Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL-Center for Personalized Cancer Medicine, Innsbruck, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-013-0071-8DOI Listing
April 2014

Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.

Leuk Res Treatment 2014 23;2014:421723. Epub 2014 Mar 23.

Division of Clinical Research, Fred Hutchinson Cancer Research Center, P.O. Box 19024, Seattle, WA 98109, USA ; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/421723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981457PMC
April 2014

Chronic Myelogenous Leukemia, Version 1.2014.

J Natl Compr Canc Netw 2013 Nov;11(11):1327-40

From 1The University of Texas MD Anderson Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 6Memorial Sloan-Kettering Cancer Center; 7Dana-Farber/Brigham & Women's Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 10Massachusetts General Hospital Cancer Center; 11Stanford Cancer Institute; 12Vanderbilt-Ingram Cancer Center; 13Fox Chase Cancer Center; 14Duke Cancer Institute; 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 16Moffitt Cancer Center; 17University of Alabama at Birmingham Comprehensive Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 20City of Hope Comprehensive Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105PMC
http://dx.doi.org/10.6004/jnccn.2013.0157DOI Listing
November 2013

Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?

Clin Adv Hematol Oncol 2013 Nov;11(11 Suppl 17):1-15

Weill Cornell Medical College /New York Presbyterian Hospital, New York, New York.

View Article

Download full-text PDF

Source
November 2013

Genetically informed therapy in leukemia.

Authors:
Jerald Radich

N Engl J Med 2013 May;368(19):1838-9

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMe1302363
Publisher Site
http://dx.doi.org/10.1056/NEJMe1302363DOI Listing
May 2013

Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia.

Authors:
Jerald P Radich

J Natl Compr Canc Netw 2013 May;11(5 Suppl):663-6

Molecular Oncology Lab, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington 98109- 1024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0196DOI Listing
May 2013

Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.

J Natl Compr Canc Netw 2013 Mar;11(3):308-15

From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0042DOI Listing
March 2013

An evolutionary explanation for the presence of cancer nonstem cells in neoplasms.

Evol Appl 2013 Jan 26;6(1):92-101. Epub 2012 Nov 26.

Genomics and Computational Biology Program, Department of Biology, University of Pennsylvania Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/eva.12030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567474PMC
January 2013

Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.

Clin Adv Hematol Oncol 2012 Oct;10(10 Suppl 19):1-16

Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
October 2012